Kinase Inhibitor News and Research

RSS

A protein kinase inhibitor is a type of enzyme inhibitor that specifically blocks the action of one or more protein kinases.

Relapsed mantle cell lymphoma patients may benefit from CAR T-cell therapy

A one-year follow-up study led by The University of Texas MD Anderson Cancer Center revealed a majority of patients with mantle cell lymphoma resistant to prior therapies may benefit from treatment with CD19-targeting chimeric antigen receptor (CAR) T-cell therapy.

9 Dec 2019

Ibrutinib-based therapy provides superior clinical outcomes in majority of CLL patients

The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) today announced results from an extended follow-up analysis of patients in its randomized Phase 3 clinical trial, E1912.

8 Dec 2019

New treatment could make passing kidney stones faster and less painful

Every year, more than half a million Americans visit the emergency room for kidney stone problems. In most cases, the stones eventually pass out of the body on their own, but the process can be excruciatingly painful.

2 Dec 2019

Juvenile immune arthritis – new treatments wanted

Juvenile immune arthritis (JIA) is a severely undertreated condition, and new medications are badly needed to relieve the signs and symptoms of the illness, according to a new study presented at the 2019 ACR/ARP Annual Meeting.

11 Nov 2019

UCLA researchers discover new way to eliminate leukemia stem cells

The introduction of the drug imatinib in 2001 revolutionized the treatment of a type of cancer called chronic myelogenous leukemia. In more than 80% of people with CML who received the drug, the disease went into complete remission.

15 Oct 2019

RTKI drugs may not significantly improve survival rates of patients during radiotherapy

Taking certain cancer-fighting drugs while undergoing radiation therapy may not increase survival for patients, but may, instead, increase side effects, according to a team of researchers. The drugs, however, may be beneficial for patients who are not undergoing radiation therapy.

10 Oct 2019

Study may help in personalizing treatment for lung cancer, develop new drugs

Researchers at the University of Copenhagen have used highly sophisticated molecular analyses to identify key proteins in the signaling pathways that cancers use to spread in the body.

4 Oct 2019

Researchers find new target for disease of the heart's smallest blood vessels

When we race walk, for example, part of our healthy heart muscle may want a little more blood and oxygen, so our tiniest blood vessels send a message upstream to the larger vessels to send more.

12 Aug 2019

New drug combinations and dosing schedules improve outlook in advanced colon cancer

Advanced colon cancer often spreads widely and may not respond to standard chemotherapy. In such a case, a novel combination of drugs and flexible dosing may help achieve a better outlook, as demonstrated by several new studies.

8 Jul 2019

Study suggests usefulness of more flexible dose of regorafenib to relieve side-effects in mCRC patients

Medical oncologists administer anticancer drug regorafenib to try to improve overall survival in patients with metastatic colorectal cancer who have ceased to respond to standard therapy (known as refractory mCRC).

7 Jul 2019

Study shows how SIRT1 plays key role in maintaining the regenerative potential of leukemic stem cells

Patients with chronic myeloid leukemia can be treated with tyrosine kinase inhibitors. While these effective drugs lead to deep remission and prolonged survival, primitive leukemia stem cells resist elimination during the remission and persist as a major barrier to cure.

11 Jun 2019

Still-to-be-approved drug proves to be new option for treating active rheumatoid arthritis

In a large-scale, international study led by renowned rheumatologist Josef Smolen from the Department of Medicine III, a still-to-be-approved drug containing the selective janus kinase inhibitor upadacitinib has proved itself to be a new option for treating active rheumatoid arthritis.

7 Jun 2019

Researchers discover unique approach to treat some chronic inflammatory diseases

Inflammation is a balanced physiological response -- the body needs it to eliminate invasive organisms and foreign irritants, but excessive inflammation can harm healthy cells, contributing to aging and chronic diseases.

12 Apr 2019

Scientists use a promiscuous inhibitor to uncover cancer drug targets

Scientists at Harvard Medical School and the Dana-Farber Cancer Institute have developed a method that exploits the multitargeted nature of a chemical inhibitor to pinpoint vulnerabilities within cancer cells.

5 Apr 2019

FDA extends indication of metastatic breast cancer treatment to include male patients

The U.S. Food and Drug Administration today is extending the indication of Ibrance (palbociclib) capsules in combination with specific endocrine therapies for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in male patients.

5 Apr 2019

Understanding maintenance of quiescent stem cells in chronic myelogenous leukemia

Most patients with chronic myelogenous leukemia can be treated with tyrosine kinase inhibitors. These drugs are highly effective and lead to deep remission and prolonged survival.

22 Mar 2019

New research finds how cancer cells acquire resistance to molecular-targeted drugs

Although molecular-targeted drugs have been known to show high efficacy to lung cancer patients, they also have limitations due to acquiring resistance to the drug used.

25 Feb 2019

Researchers discover origin of resistance to lung cancer

For treating cancer, drugs based on molecules known as tyrosine kinase inhibitors are sometimes used. One such tyrosine kinase inhibitor, called osimertinib, has been used to treat EGFR-mutated lung cancer with a certain degree of efficacy.

25 Feb 2019

Bio-Rad launches new digital PCR system and kit for monitoring treatment response in CML patients

Bio-Rad Laboratories, Inc., a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad's Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry's first digital PCR products to receive U.S. Food and Drug Administration clearance.

15 Feb 2019

Researchers identify promising therapeutic option to treat multiple sclerosis

Researchers at the Medical Center of Johannes Gutenberg University Mainz (JGU) identified an innovative and promising therapeutic option to treat multiple sclerosis.

10 Jan 2019